OrthoTreat develops ModulX®, a dual-drug combination therapy that utilizes osteoregulation to enhance the physiological processes of bone tissue regeneration. This approach addresses the slow healing of bone injuries by optimizing the healing environment rather than merely supplying materials for bone formation.
Funding
Funding not disclosed
Founders
Product
Problem
Long bone fractures and other bone injuries often exhibit slow or incomplete healing, leading to prolonged recovery times and increased risk of complications. Current treatments primarily focus on providing materials for bone formation, neglecting the optimization of the body's natural healing processes. This can result in suboptimal bone regeneration and functional recovery.
Solution
OrthoTreat is developing ModulX®, a dual-drug combination therapy designed to enhance bone tissue regeneration through osteoregulation. This approach focuses on optimizing the physiological processes involved in bone healing, rather than simply supplying building blocks. ModulX® acts as a regulator of the bone healing environment, managing various aspects of bone regeneration to promote faster and stronger healing. The therapy aims to improve bone growth, reduce bone loss, enhance bone quality and strength, and accelerate overall healing times.
Target Audience
The primary target audience includes orthopedic surgeons, sports medicine physicians, and patients with long bone fractures, non-union fractures, and other bone injuries requiring enhanced regeneration.
Features
- Dual-drug combination therapy for enhanced bone regeneration
- Osteoregulation approach to optimize the body's natural healing processes
- Focus on managing the bone healing environment for comprehensive regeneration
- Designed to improve bone growth, reduce bone loss, and enhance bone quality
- Aims to accelerate healing times for bone fractures and injuries